Close Menu

Veracyte

News items for the in vitro diagnostics industry for the week of March 15, 2021.

For the three months ended Dec. 31, 2020, the firm posted $34.5 million in revenues, up from $29.7 million in 2019 and beating analysts' estimate of $31.9 million.

News items for the in vitro diagnostics industry for the week of Feb. 8, 2021.

The firm will use the net proceeds for its planned $600 million acquisition of Decipher Biosciences, working capital, and other general corporate purposes.

Decipher will remain a wholly owned subsidiary of Veracyte, which plans to integrate Decipher's urologic cancer tests on its nCounter platform.

San Diego-based Decipher has a portfolio of genomic tests for urologic cancers to improve patient decision-making and accelerate adoption of new therapies.   

Bayer will offer Veracyte's Afirma Xpression Atlas to identify underlying drivers in tumors of late-stage or metastatic thyroid cancer patients resistant to radioactive iodine therapy.

Quidel and Accelerate Diagnostics had the biggest declines in their share prices as the Index lagged behind the broader markets.

Veracyte reported total Q3 revenues of $31.1 million compared to $31.0 million in Q3 2019, beating analysts' average of $23.9 million.

Pages